STAGE IVA BLADDER CANCER AJCC V8
Clinical trials for STAGE IVA BLADDER CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVA BLADDER CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IVA BLADDER CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy plus chemo shows promise against tough cancers
Disease control OngoingThis early-phase trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate that have spread. About 15 participants will receive the combinatio…
Matched conditions: STAGE IVA BLADDER CANCER AJCC V8
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 10, 2026 13:27 UTC
-
Bladder cancer drug combo trial pulled before enrolling a single patient
Disease control TerminatedThis study was designed for people with muscle-invasive bladder cancer who cannot receive the standard chemotherapy drug cisplatin. It aimed to compare the effects of taking erdafitinib alone versus erdafitinib combined with atezolizumab before surgery. However, the trial was wit…
Matched conditions: STAGE IVA BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 05, 2026 12:08 UTC
-
New hope for bladder cancer patients who can't take chemo
Disease control OngoingThis study tests a combination of radiation therapy and two immunotherapy drugs (durvalumab with or without tremelimumab) in people with advanced bladder cancer that cannot be surgically removed or has spread. Participants either cannot have chemotherapy or have chosen not to. Th…
Matched conditions: STAGE IVA BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 26, 2026 12:03 UTC
-
Can a simple test predict who will respond to immunotherapy?
Knowledge-focused OngoingThis study looks at whether certain gene mutations (ARID1A and KDM6A) and a protein called CXCL13 in tumors can help predict if the immunotherapy drug nivolumab will work for people with advanced bladder cancer that has spread. Only 6 participants with these specific gene changes…
Matched conditions: STAGE IVA BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 17, 2026 12:08 UTC